INSIGHTS ON DRUG DEVELOPMENT
-
Maintain Control Of Pharmaceutical Water Systems
Early TOC excursions often reveal hidden risks in water systems. Capturing samples at the moment of deviation helps teams confirm root causes faster, reduce uncertainty, and maintain control.
-
Aggregation In Antibody-Drug Conjugates: Causes And Mitigation
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Enabling Quality By Design
Outdated quality systems delay product release. Discover how manufacturers can harness real-time data, operationalize QbD, and enhance compliance, efficiency, and supply chain continuity.
-
UPLC-MS/MS Determination Of GLP-1 Analogue
Discover a robust, evaporation-free method for analyzing liraglutide in human plasma using LC-MS/MS to ensure high sensitivity, reproducibility, and improved analyte recovery.
-
Advancing GLP-1 Analog Drug Development Using A Variety Of Techniques6/27/2025
Discover how SEC-MALS reveals the aggregation behavior of GLP-1 analogs like semaglutide and liraglutide, which are critical for ensuring the stability, efficacy, and safety of peptide therapeutics.
-
Doubling Up For Speed In Biomanufacturing12/12/2025
Accelerate drug development and reduce risk with parallel operations. Learn how leveraging CDMO partnerships while building internal capabilities can cut costs and speed your path to market.
-
Enhanced Validation Data Anti-EGFRvIII Recombinant Antibody3/24/2025
Select the right antibody clone by exploring enhanced validation data for top recombinant antibody clones that offer comprehensive specificity and sensitivity insights tailored to your project's unique requirements.
-
Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development3/3/2026
Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.
-
Improving API Solubility With Mesoporous Silica6/5/2025
Poor solubility of active pharmaceutical ingredients can hinder drug effectiveness. Learn how innovative formulation strategies enhance solubility and bioavailability to improve therapeutic outcomes for challenging drug candidates.
DRUG DEVELOPMENT SOLUTIONS
-
Designed for today’s assays and tomorrow’s breakthroughs—flexible detection that evolves with your science.
The SpectraMax® iD3s and iD5e Multi-Mode Microplate Readers deliver flexible, scalable solutions for absorbance, fluorescence, and luminescence assays—with advanced capabilities for evolving research needs. The iD3s reader offers a streamlined, affordable platform with a tunable monochromator and temperature control, while the iD5e reader adds enhanced detection modes including time-resolved fluorescence (TRF) and tunable fluorescence polarization (FP) and can be expanded to include TR-FRET, HTRF, BRET and western blot. Both readers support on board fluidics with optional dual injectors.
-
Quickly address critical formulation issues and optimizing performance. Explore services for small molecules and synthetic peptides across oral, topical, rectal, and parenteral routes.
-
Are you using obsolete or aging instruments simply because they continue to work? Running your laboratory with outdated technology brings about challenges beyond just headaches. Older technology may limit your performance, increase your costs, and open your lab up to risk. It may be time to investigate the real cost of using obsolete technology.
With the Waters FlexUP Technology Renewal Program, always work with the latest technology for optimum productivity and security.
-
By harnessing cutting-edge microcalorimetry technology, researchers can unravel the complexities of molecular interactions, paving the way for groundbreaking discoveries in drug development.
-
Upperton have developed UpperNose™, a nasal product development approach designed to streamline the development process for nasal dosage forms.